Abstract

PurposeIncreased ATP-binding-cassette (ABC) transporter activity is a major cause of chemotherapy resistance in cancer. The ABC transporter family member ABCB1 is often overexpressed in colorectal cancer (CRC). Phosphatidylinositol-4,5-bisphosphat (PI(4,5)P2)-dependent pathways are involved in the regulation of ABCB1 function. The protein Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) is a pivotal regulator of PI(4,5)P2 and inactivated in many CRC cancers via genetic deletion or hyperphosphorylation. Therefore, MARCKS may critically impact ABCB1.MethodsCRC samples as well as CRC cell lines were tested for a connection between MARCKS and ABCB1 via immunofluorescence and Western-blot analysis. ABCB1 function was studied via calcein influx assay under treatment with known ABCB1 inhibitors (verapamil, tariquidar) as well as the kinase inhibitor bosutinib. ABCB1 internalization and MARCKS translocation was analyzed via confocal microscopy exploiting the endocytosis inhibitors chlorpromazine and dynasore. Abundance of PI(4,5)P2 was monitored by intramolecular fluorescence resonance energy transfer (FRET). Reproductive cell survival was studied via colorimetric WST-1 and clonogenic assays in combination with exposure to the chemotherapeutics doxorubicin and 5-fuorouracil (5-FU).ResultsWe found increased ABCB1 expression in MARCKS negative CRC patient tumor samples and established CRC cell lines. Mechanistically, the reconstitution of MARCKS function via recombinant expression or the pharmacological inhibition of MARCKS phosphorylation led to a substantial decrease in ABCB1 activity. In CRC cells, bosutinib treatment resulted in a MARCKS translocation from the cytosol to the plasma membrane, while simultaneously, ABCB1 was relocated to intracellular compartments. Inhibition of MARCKS phosphorylation via bosutinib rendered cells more sensitive to the chemotherapeutics doxorubicin and 5-FU.ConclusionsCells devoid of MARCKS function showed incomplete ABCB1 internalization, leading to higher ABCB1 activity enhancing chemoresistance. Vice versa our data suggest the prevention of MARCKS inhibition by reversing hyperphosphorylation or genomic restoration after deletion as two promising approaches to overcome tumor cell resistance towards chemotherapeutic ABCB1 substrates.

Highlights

  • Development of resistance against chemotherapy is one of the main causes of tumor relapse (Borst and Schinkel 2013; Colabufo 2008; Katayama 2014)

  • If the antitumor effects of Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) are dependent on its ability to interact with PI(4,5)P2, colorectal cancer (CRC) cells with hyperphosphorylated MARCKS should behave like CRC cells with absent MARCKS

  • Using HT-29 cells as a model for MARCKS hyperphosphorylation, we present evidence that the tyrosine kinase inhibitor bosutinib can restore MARCKS function in a tumor context

Read more

Summary

Introduction

Development of resistance against chemotherapy is one of the main causes of tumor relapse (Borst and Schinkel 2013; Colabufo 2008; Katayama 2014). In many solid tumors including colorectal carcinoma (CRC), the upregulation of ATP-binding cassette (ABC) transporters has been linked to resistance against various chemotherapeutics (Borst and Schinkel 2013; Colabufo 2008). ABCB1 ( known as P-gp, or as multidrug resistance protein 1, MDR1), is localized in lipid rafts and functions as an broad spectrum transporter, shuttling mostly lipophilic chemicals out of a cell, thereby minimizing the toxic effects of potentially harmful substances (Borst and Schinkel 2013; Lavie et al 1998; Mercier 2012). Due to its electrostatic properties MARCKS binds and sequesters PI(4,5)P2. This reduces the accessible lipid pool and by this means regulates signal transduction. Upon phosphorylation by protein kinase C (PKC) or the oncogenic tyrosine kinase c-Abl, MARCKS dissociates from the membrane, releasing PI(4,5)P2 for interaction with other target proteins

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.